AOD-9604 Research Peptide (RUO)

What is AOD-9604?

AOD-9604 is a synthetic 16-amino-acid peptide derived from the C-terminal lipolytic region of human growth hormone: the hGH(177-191) fragment with an additional tyrosine residue at the N-terminus (Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe). The two cysteine residues form a single intramolecular disulfide bond. Its CAS number is 221231-10-3, with molecular formula C78H123N23O23S2 and a molecular weight of approximately 1815.10 g/mol.

Mechanistically, AOD-9604 has been studied in vitro and in preclinical models as a modulator of adipocyte fat metabolism, where it has been reported to stimulate lipolysis and reduce lipogenesis without the carbohydrate-metabolism effects (such as changes in blood glucose, insulin sensitivity or IGF-1) associated with full-length growth hormone. Importantly, AOD-9604 is not approved by the FDA, EMA or other major regulators for therapeutic use; clinical development as an anti-obesity agent did not lead to approval.

How AOD-9604 Is Produced & Characterised

AOD-9604 is a disulfide-bridged hexadecapeptide, and its production carries the usual short-peptide challenges: complete coupling of each residue, correct regioselective formation of the single Cys-Cys disulfide bond, and avoidance of scrambled or dimeric by-products. The peptide is generally prepared by Fmoc solid-phase peptide synthesis (SPPS), followed by controlled oxidative folding to set the correct disulfide, then purification on preparative dynamic axial compression (DAC) HPLC columns to resolve the target sequence from deletion sequences and disulfide isomers, and lyophilisation to a stable, uniform powder.

Analytical characterisation of a peptide of this class typically combines UPLC/HPLC for purity determination with LC-MS to confirm the sequence and to profile minor structural variants such as disulfide isomers and deletion sequences. This is the general industry approach for short, cysteine-bridged peptides.

Regulatory & Approval Context

AOD-9604 is not an approved active pharmaceutical ingredient. It is not approved by the FDA, EMA or other major regulators for therapeutic use, and its clinical development as an anti-obesity agent did not lead to approval. As a result it has no marketing authorisation as a finished therapeutic in major jurisdictions.

Where AOD-9604 appears in research, analytical or method-development contexts, it is handled as a research chemical or reference standard rather than as a medicine, and any associated characterisation data (identity, purity, impurity profiling and stability) is used to support analytical qualification and traceability. No efficacy or therapeutic-benefit claims are established for AOD-9604.

Research supply from Winhycare Pharma

Winhycare Pharma supplies research-grade AOD-9604 to research organisations and individual researchers for research and development purposes. Material is supplied at high purity (>99%) under stringent quality control with QC documentation, in secure packaging through global standard logistics, with dedicated technical assistance from our team. We focus on consistent quality and purity, reliable and timely supply, confidential and professional service, and long-term partnerships.

Research use only. Not for human or veterinary use, and not for use in food, drugs, medical devices or cosmetics.

To enquire, tell us the quantity you need, the purity grade, the documentation you require and the destination country. The buyer is responsible for complying with the import and use regulations that apply to AOD-9604 in their country.